A-激酶锚定蛋白8L（AKAP8L）属于A-激酶锚定蛋白（AKAP）家族。最近的研究证明了AKAP8L与各种肿瘤的进展有关。为了更全面地了解AKAP8L在不同类型癌症中的意义，我们对多个组织学数据集进行了详细分析，包括全癌基因表达水平、生物学功能、分子特性，以及AKAP8L在全癌的诊断和预后价值。此外，我们还重点关注了肾透明细胞肾癌（KIRC），并探讨了AKAP8L与临床特征、不同患者亚群体的预后、共表达基因和差异表达基因（DEG）的相关性。我们还进行了AKAP8L建立的单克隆抗体的免疫组织化学染色和半定量验证。我们的研究结果表明，AKAP8L的表达在大多数癌症类型以及不同癌症分子和免疫亚型中都存在显著差异。此外，AKAP8L具有准确预测癌症的强大能力，并且与癌症预后强烈相关，这表明AKAP8L可能是癌症诊断和预后的潜在生物标志物。此外，AKAP8L的高表达水平与KIRC的总体生存（OS）、疾病特定生存（DSS）以及无进展生存期（PFI）显著相关，尤其是在不同临床亚组中。总之，AKAP8L有潜力作为诊断和预后的关键分子生物标志物，在KIRC中作为独立的预后风险因子，并且是癌症治疗的新的分子靶标。

A-kinase anchoring protein 8L (AKAP8L) belong to the A-kinase anchoring protein (AKAP) family. Recent studies have proved that AKAP8L is associated with the progression of various tumors. To establish a more complete understanding of the significance of AKAP8L across various types of cancers, we conducted a detailed analysis of multiple histological datasets, including the level of gene expression in pancancer, biological function, molecular characteristics, as well as the diagnostic and prognostic value of AKAP8L in pancancer. Furthermore, we focused on renal clear cell carcinoma (KIRC), and of explored the correlation of AKAP8L with clinical characteristics, prognosis of distinct patient subsets, co-expression genes and differentially expressed genes (DEG). We also performed the immunohistochemical staining and semi-quantitative verification of the monoclonal antibody established by AKAP8L. Our findings indicate that AKAP8L expression varied significantly not only across most cancer types, but also across different cancer molecules and immune subtypes. In addition, the robust ability to accurately predict cancer and its strong correlation with the prognosis of cancer strongly suggest that AKAP8L may be a potential biomarker for cancer diagnosis and prognosis. Furthermore, the high expression levels of AKAP8L were related to the worse overall survival (OS), disease-specific survival (DSS) as well as progression-free interval (PFI) of KIRC with statistical significance, especially among distinct clinical subgroups of KIRC. To sum up, AKAP8L has the potential to serve as a critical molecular biomarker for the diagnosis and prognosis of pancancer, an independent prognostic risk factor of KIRC, and a novel molecular target for cancer therapies.